Timothée Olivier, Medical Oncologist and Attending Physician at the Oncology Division of Geneva University Hospital in Switzerland, shared on X:
“NATALEE 6-y results are out!
2.1 delta in survival at 6 years. Thanks Annals of Oncology for reporting subsequent therapy data!
Only 44.4% of control arm patients with distant recurrence received a first-line CDK4/6i.
Does this survival difference truly inform clinical practice in settings where CDK4/6i are standard of care for metastatic disease?
In my opinion, the answer is no.”
Some interesting highlights from ESMO 2026:
